WALTHAM, Mass. — Innoviva Specialty Therapeutics said three of its infectious disease therapies have been named finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category.
The finalists are XACDURO (sulbactam/durlobactam for injection), ZEVTERA (ceftobiprole medocaril sodium for injection) and NUZOLVENCE (zoliflodacin). Innoviva Specialty Therapeutics is a subsidiary of Innoviva Inc.
The recognition marks the third consecutive year that an Innoviva Specialty Therapeutics product has been selected as a Prix Galien finalist.
“This is the broadest slate of IST products to be designated as Prix Galien finalists, which is a testament to the clinical significance of the IST portfolio,” said Pavel Raifeld, Chief Executive Officer of Innoviva. “Each of these therapies addresses a distinct front in the fight against drug-resistant infections, and this nomination is further validation of our efforts to deliver life-saving medicines to patients.”
The Prix Galien USA Awards recognize advances in the biopharmaceutical and medical technology industries based on their potential to improve human health. Winners of the 2026 awards are scheduled to be announced Oct. 29 in New York City.
“As the public health crisis of antimicrobial resistance further progresses, innovative therapeutics will continue to play an outsized role,” said David Altarac, M.D., Chief Medical Officer at Innoviva Specialty Therapeutics. “To that end, considering that AMR is estimated to be associated with significant morbidity and millions of deaths worldwide each year, we’re privileged to be recognized for making notable strides in providing treatment for such difficult-to-treat infections.”
XACDURO was approved by the U.S. Food and Drug Administration in May 2023 for hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of the Acinetobacter baumannii-calcoaceticus complex.
ZEVTERA received FDA approval in April 2024 for several indications, including Staphylococcus aureus bloodstream infections in adults, acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.
NUZOLVENCE was approved by the FDA in December 2025 as a single-dose oral treatment for urogenital gonorrhea. It was developed through a collaboration between Innoviva Specialty Therapeutics and the Global Antibiotic Research and Development Partnership.
The Prix Galien was established in France in 1970 and honors scientific and medical innovations. To qualify for a Prix Galien USA Award, a candidate product must generally have received FDA marketing approval within the previous five years and demonstrate significant potential to improve human health.
